Evaluation of a Nutritional Technology for Vitamin D Absorption

Inclusion criteria

• Adult participants (18-55 years of age)
• Body mass index (BMI) <30 kg/m2
• Males and nonpregnant, nonlactating females
• Free of gastrointestinal disorders that my impact nutrient absorption in the small intestine, endocrine, hepatic, renal, or bone diseases

Exclusion criteria

• Use of vitamin D or calcium supplements within 3 weeks prior to the Screening Visit.
• Use of a tanning booth/lamp within 3 weeks prior to the Screening Visit.
• Travel to sunny location within 3 weeks prior to the Screening Visit.
• Consumption of more than 3 alcoholic drinks per day starting 48 hours before the Screening Visit.
• Has an allergy or intolerance to any ingredient in the study product.
• Participating in another study that has not been approved as a concomitant study by Abbott Nutrition.
• Use of the following medications that may have interactions with vitamin D absorption or metabolism:

• Aluminum-containing phosphate binders
• Anticonvulsants
• Atorvastatin
• Calcipotriene
• Cholestyramine
• Cytochrome P-450 3A4 substrates
• Digoxin
• Diltiazem
• Orlistat
• Thiazide diuretics
• Corticosteroids
• Stimulant laxatives
• Verapamil